New hope for kids with rare epilepsy: drug trial targets seizure control

NCT ID NCT07010471

Ongoing Disease control Sponsor: Praxis Precision Medicines Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study tests an investigational drug called relutrigine in 160 children with a severe form of epilepsy called developmental and epileptic encephalopathy (DEE). The goal is to see if the drug can safely reduce monthly seizure frequency compared to a placebo. After the initial blinded phase, all participants can receive the drug in an open-label extension.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

developmental and epileptic encephalopathy developmental and epileptic encephalopathy, 1 epilepsy infantile epileptic-dyskinetic encephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1

Contacts and locations

Locations

Praxis Research Site

La Jolla, California, 92037, United States
Praxis Research Site

Gulf Breeze, Florida, 32561, United States
Praxis Research Site

Chevy Chase, Maryland, 20815, United States
Praxis Research Site

Roseville, Minnesota, 55113, United States
Praxis Research Site

Hackensack, New Jersey, 07601, United States
Praxis Research Site

Philadelphia, Pennsylvania, 19104, United States
Praxis Research Site

Heidelberg, Victoria, 3084, Australia
Praxis Research Site

Rio Grande, Do Sul, 90610, Brazil
Praxis Research Site

Paraná, 80250, Brazil
Praxis Research Site

Rio de Janeiro, 20231, Brazil
Praxis Research Site

São Paulo, 15090, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.